Key Takeaways
- After a hip or knee replacement, patients take a blood thinner for about a month because immobility and surgery raise the risk of dangerous clots.
- PEPPER found aspirin could not prove itself equal to stronger anticoagulants on clots — but the stronger drugs could not prove themselves equal to aspirin on safety either.
- EPCAT III, a Canadian trial published in July, found a few days of a stronger drug followed by aspirin worked as well as staying on it — a different question, a different answer.
Why everyone goes home with a blood thinner
After a New Hip or Knee, Which Blood Thinner Wins?
You've had your hip or knee replaced. Now comes another important part of recovery: preventing a blood clot.
Surgery, reduced mobility and the body's healing response can all increase clotting. A clot in the leg can travel to the lungs.
That's why joint-replacement patients have long been sent home with roughly a month of clot prevention.
But which medication should they take?
Aspirin is cheap, familiar and relatively gentle. Warfarin is powerful but requires blood-test monitoring. Rivaroxaban is a modern anticoagulant taken once daily without routine monitoring.
For years, smaller studies made aspirin look promising. Many surgeons hoped the simplest option might be enough.
Now, two major trials offer a more complicated answer.
Nearly 19,000 Patients. Three Drugs. No Clear Winner.
The PEPPER trial, published this week in The New England Journal of Medicine, randomized 18,883 hip- and knee-replacement patients to 30 days of aspirin, warfarin or rivaroxaban.
Researchers followed them for six months.
Here is what happened.
Death or a symptomatic blood clot occurred in:
Aspirin: 1.26%
Warfarin: 1.23%
Rivaroxaban: 0.94%
Rivaroxaban had the lowest rate.
But the trial's statistical conclusion matters: aspirin could not demonstrate that it was non-inferior — meaning not unacceptably worse — than either anticoagulant at preventing clots and death.
So does that make rivaroxaban the winner?
Not so fast.
The Safety Results Tell Another Story
The researchers also examined bleeding, wound problems requiring another operation, and heart attacks.
This time, aspirin had the lowest rate.
Aspirin: 2.91%
Warfarin: 3.36%
Rivaroxaban: 3.48%
And the statistical verdict went the other way.
Neither anticoagulant could demonstrate non-inferiority to aspirin on the safety outcome.
In other words, aspirin could not prove it was as effective at preventing clots and death, while the anticoagulants could not prove they were as safe.
Nobody won both halves of the argument.
But Didn't a Canadian Trial Find Aspirin Was Fine?
Largely, yes. But there is an important distinction.
EPCAT III, a Canadian trial published in July 2026, studied more than 5,400 patients.
Researchers compared two approaches:
Aspirin alone.
Rivaroxaban for the first five days, followed by aspirin.
Blood clots were rare in both groups: 0.48% versus 0.45%.
The five-day rivaroxaban head start added no measurable benefit.
That sounds different from PEPPER, but the studies asked different questions.
EPCAT III examined whether starting with rivaroxaban and switching to aspirin improved outcomes compared with aspirin alone.
PEPPER compared aspirin, warfarin and rivaroxaban across a full 30-day course.
And PEPPER could not establish that aspirin was non-inferior to the anticoagulants on its primary effectiveness outcome.
The distinction matters.
A trial finding no measurable benefit from a five-day head start is not the same as proving aspirin is equally effective across a full month.
What Should Patients Actually Do?
The differences reported in these trials are fractions of a percentage point.
That makes the findings important for doctors and researchers, but they are not instructions to change your own prescription.
Which drug you take, at what dose and for how long, depends on your surgical team's assessment of your individual risks.
Take the full prescribed course. Keep moving as your team directs.
And don't ignore warning signs.
New leg swelling or pain, chest pain, breathlessness or unusual bleeding require immediate medical attention — not a wait until after the weekend.
The Twikup Take
Two major trials. Two findings that initially seem to disagree.
But the bigger picture is consistent.
Clots after joint replacement are now rare — about one patient in a hundred or fewer.
Aspirin comes close, but PEPPER could not prove it was non-inferior over the full course.
And EPCAT III found no measurable benefit from giving rivaroxaban for the first five days before switching to aspirin, compared with aspirin alone.
The evidence isn't delivering one universal winner. It's narrowing the questions doctors still need to answer.
The best blood thinner isn't necessarily the strongest or the simplest — it's the one that best balances clot prevention and safety for the patient.
Health note: Do not stop, switch or adjust prescribed blood thinners based on these trial findings. Follow your surgical team's instructions and seek immediate medical attention for possible clotting or bleeding symptoms.
Image: Illustrative image.